![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, June 08, 2024 11:26:08 AM
Dr. Waltzman will present preliminary results from the Company’s ongoing Phase 1 study of Decoy20, an intravenous treatment using killed bacteria designed to broadly stimulate the immune system, in patients with advanced solid tumors.
Jeffrey Meckler, Indaptus CEO commented, “We are excited to share our latest findings from our Phase 1 clinical trial of Decoy20, and we are grateful for the opportunity to be invited to provide continued updates. We remain optimistic regarding the results seen to date and anticipate providing continued updates as they develop.”
$$$$
Recent INDP News
- Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit • GlobeNewswire Inc. • 06/11/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:30:38 PM
- Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference • GlobeNewswire Inc. • 06/04/2024 12:00:00 PM
- Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20 • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 12:00:18 PM
- Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors • GlobeNewswire Inc. • 05/22/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 12:06:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 12:05:19 PM
- Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/08/2024 12:00:00 PM
- Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference • GlobeNewswire Inc. • 03/28/2024 12:00:00 PM
- Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting • GlobeNewswire Inc. • 03/25/2024 12:30:00 PM
- Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024 • GlobeNewswire Inc. • 03/18/2024 12:00:00 PM
- Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/13/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 04:01:33 PM
- Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort • GlobeNewswire Inc. • 03/04/2024 12:30:00 PM
- Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels • GlobeNewswire Inc. • 02/08/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 09:15:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:05:34 PM
- European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2023 09:06:25 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM